Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ANRS 12404 TIMPANI: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis: a Phase II, Multicenter, Randomized Clinical Trial

NCT05590455 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.

NCT NCT05590455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05590455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ANRS 12404 TIMPANI: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis: a Phase II, Multicenter, Randomized Clinical Trial
Lead sponsor
ANRS, Emerging Infectious Diseases
Phase
Phase 2
Overall status
Recruiting
Start date
April 11, 2023
Completion date
December 31, 2027
Enrollment
130 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv i infection, tuberculous meningitis